558 related articles for article (PubMed ID: 17113893)
21. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
[TBL] [Abstract][Full Text] [Related]
22. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
[TBL] [Abstract][Full Text] [Related]
23. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
24. Redefining response in overactive bladder syndrome.
Payne CK; Kelleher C
BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
[TBL] [Abstract][Full Text] [Related]
25. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
[TBL] [Abstract][Full Text] [Related]
26. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
27. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
29. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
30. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Staskin DR; Te AE
BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
[TBL] [Abstract][Full Text] [Related]
31. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
Millard RJ; Halaska M
Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
[TBL] [Abstract][Full Text] [Related]
33. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
35. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
37. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
38. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Nelken RS; Ozel BZ; Leegant AR; Felix JC; Mishell DR
Menopause; 2011 Sep; 18(9):962-6. PubMed ID: 21532512
[TBL] [Abstract][Full Text] [Related]
40. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
Wein AJ; Khullar V; Wang JT; Guan Z
BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
